Tradestie Institutional Equity Comparison Engine

RKTO vs PHIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PHIO Overall Edge

PHIO Captures Institutional Edge (3โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Phio Pharmaceuticals Corp. Common Stock (PHIO) driven by superior Valuation, Growth & Margin, Momentum & Technical. Fundamentally, RKTO trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus PHIO at 0.3x Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RKTO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PHIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PHIO
RKTO N/M vs PHIO 0.3x Fwd P/E
Growth & Margin Winner PHIO
Op Margin N/A vs 0.0% ยท YoY N/A vs +0.0%
Momentum & Technical Winner PHIO
1Y -82.5% vs -47.5% ยท 52W Pos 2% vs 1%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
RKTO US Equity
RKTO
Institutional Equity
$0.30
+6.11% 1D
Market Cap N/A
1M Return -44.23%
1Y Return -82.53%
Forward P/E N/M
Unified AI Score
44.2 / 100 HOLD
Tech 45.0 Fund 42.0 Flow 50.0 Mom 55.0
PHIO NASDAQ
Phio Pharmaceuticals Corp. Common Stock
Pharmaceutical Preparations
$0.66
-8.25% 1D
Market Cap $8.5M
1M Return -24.81%
1Y Return -47.52%
Forward P/E 0.3x
Unified AI Score
41.2 / 100 SELL
Tech 25.0 Fund 46.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RKTO -82.53% PHIO -47.52% Spread: +40.07 pp (PHIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
RKTO TTM Op. Margin: N/A PHIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RKTO vs PHIO. Trailing 12-month operating profitability (RKTO N/A vs PHIO 0.0%) and valuation multiples (RKTO N/M vs PHIO 0.3x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RKTO (1) vs PHIO (8)
Institutional Metric RKTO PHIO Criterion Row Winner
Market Capitalization Scale N/A $8.5M Larger Scale PHIO
Trailing P/E Ratio Valuation N/M 0.3x Lower Multiple PHIO
Forward P/E Ratio Valuation N/M 0.3x Lower Multiple PHIO
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth PHIO
Operating Margin (TTM) Profitability N/A 0.0% Higher Margin PHIO
Net Profit Margin Profitability N/A 0.0% Higher Margin PHIO
Return on Equity (ROE) Capital Efficiency N/A -159.0% Higher ROE PHIO
52-Week Range Position Momentum 2% ($0โ€“$2) 1% ($1โ€“$2) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 63% Vol 1.07ฮฒ ยท 57% Vol Lower Realized Risk PHIO
Unified Institutional Score Composite Signal 44.2 / 100 (HOLD) 41.2 / 100 (SELL) Higher Composite RKTO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RKTO vs PHIO Buy Guide
RKTO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live RKTO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PHIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PHIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RKTO nor PHIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.